Adjacent Evidence Brief: Telomere Measurement Methods

Abstract

This paper synthesizes evidence on telomere measurement methods across the retained source corpus and high-confidence extracted claim set [bundle:5].

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the source tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

Introduction

The question of whether interventions that modulate telomere biology can meaningfully extend human healthspan or lifespan has become a central challenge in contemporary geroscience. The stakes are high, as telomere attrition may represent a fundamental mechanism linking cellular aging to organismal frailty, yet the causal direction and clinical utility of measuring or modifying telomere length remain subjects of intense investigation and debate.

The geroscience hypothesis proposes that targeting fundamental aging biology, rather than individual diseases, could be a more efficient strategy to extend healthspan. Within this framework, telomere maintenance has been proposed as a key modifiable hallmark of aging. Interventions ranging from lifestyle modifications to pharmacological agents are being investigated for their potential to influence telomere dynamics. This variability underscores the complexity of telomere biology and suggests that broad lifestyle-based interventions may have modest or context-dependent effects on telomere length, necessitating a more targeted approach.

The human randomized controlled trial (RCT) landscape for telomere-focused interventions is characterized by diverse study designs, populations, and endpoints, leading to a mixed and sometimes contradictory evidence base. Many trials are mechanistic or biomarker-focused, assessing TL change as a primary or secondary endpoint without clinical outcomes. This diversity of trial contexts and populations makes it difficult to synthesize a unified narrative about the efficacy of interventions aimed at modifying telomere length.

Several critical questions remain unresolved regarding the translation of telomere biology from mechanism to clinical application. The relationship between telomere length and outcomes appears to be highly context-dependent, with effect directions that are not always consistent. The duration and dose-response of potential telomere-modifying interventions are also poorly defined, as is the question of whether changes in telomere length are causally linked to health outcomes or merely serve as a surrogate marker for other biological processes.

This synthesis aims to contribute by systematically examining the tensions between mechanistic plausibility and clinical evidence within the telomere measurement and intervention literature. A central challenge is the separation of clinical from mechanistic evidence, as findings from different outcome domains cannot be directly compared. The review will therefore weight the evidence by separating these layers: mapping the landscape of human RCTs that have directly measured telomere length change, examining the observational associations with longevity and specific diseases, and evaluating the mechanistic studies that inform biological plausibility. The goal is to identify where the evidence is consistent, where it is contradictory, and where the most significant gaps remain, particularly concerning the functional consequences of modifying telomere length and the boundary conditions for any potential clinical benefit.

Methods

Risk-of-bias honesty note: No populated per-source public appraisal ratings are reported in this artifact. Risk-of-bias language is therefore descriptive of source design and directness, not a claim that formal framework-specific scoring was completed.

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. This methods pack freezes the run-reported selection counts, extraction fields, and synthesis settings used for manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-telomere_measurement_methods-v06-DAILY-2026-08-15T07-46-51Z.

Information sources

The frozen retrieval record reports 15 enabled; 11 succeeded; 4 failed; 0 enabled without a recorded outcome. Named sources: arxiv (failed); biorxiv (succeeded); clinicaltrials (succeeded); crossref (succeeded); doaj (succeeded); europepmc (succeeded); medrxiv (succeeded); openaire (failed); openalex (succeeded); pmc oai (succeeded); pubmed (failed); researka (failed); semanticscholar (succeeded); unpaywall (succeeded); v5 fullraw (succeeded). Retrieval record date: 2026-08-14T13:21:15+00:00.

Search strategy

The following query strings are recorded in the frozen retrieval record:

• ("telomere measurement methods"[tiab] OR telomere[tiab]) AND (aging[tiab] OR "older adults"[tiab] OR elderly[tiab] OR geriatric[tiab] OR longevity[tiab] OR healthspan[tiab] OR frailty[tiab] OR sarcopenia[tiab] OR "muscle function"[tiab] OR "physical function"[tiab] OR cognition[tiab] OR cardiometabolic[tiab] OR cardiovascular[tiab] OR mortality[tiab] OR inflammation[tiab] OR biomarkers[tiab] OR safety[tiab]) AND ("clinical trial"[pt] OR "randomized controlled trial"[pt] OR "cohort study"[pt] OR "observational study"[pt] OR meta-analysis[pt] OR "systematic review"[pt]) AND English[lang] AND ("2000"[dp] : "2100"[dp]) NOT ("pediatric only"[tiab] OR "pregnancy only"[tiab] OR "case report only"[tiab] OR "cosmetic device only"[tiab] OR "sports performance only"[tiab])
• ("telomere measurement methods" OR telomere) AND (aging OR "older adults" OR elderly OR geriatric OR longevity OR healthspan OR frailty OR sarcopenia OR "muscle function" OR "physical function" OR cognition OR cardiometabolic OR cardiovascular OR mortality OR inflammation OR biomarkers OR safety) AND (PUB_TYPE:"clinical trial" OR PUB_TYPE:"randomized controlled trial" OR PUB_TYPE:"cohort study" OR PUB_TYPE:"observational study" OR PUB_TYPE:"meta-analysis" OR PUB_TYPE:"systematic review") AND LANG:eng AND PUB_YEAR:[2000 TO 2100] NOT ("pediatric only" OR "pregnancy only" OR "case report only" OR "cosmetic device only" OR "sports performance only")
• ("telomere measurement methods" OR telomere) AND (aging OR "older adults" OR elderly OR geriatric OR longevity OR healthspan OR frailty OR sarcopenia OR "muscle function" OR "physical function" OR cognition OR cardiometabolic OR cardiovascular OR mortality OR inflammation OR biomarkers OR safety) NOT ("pediatric only" OR "pregnancy only" OR "case report only" OR "cosmetic device only" OR "sports performance only")
• telomere measurement methods telomere aging older adults elderly geriatric longevity healthspan frailty sarcopenia muscle function physical function cognition cardiometabolic cardiovascular mortality inflammation biomarkers safety
• ("telomere measurement methods"[tiab] OR telomere[tiab]) AND (aging[tiab] OR "older adults"[tiab] OR elderly[tiab] OR geriatric[tiab] OR longevity[tiab] OR healthspan[tiab] OR frailty[tiab] OR sarcopenia[tiab] OR "muscle function"[tiab] OR "physical function"[tiab] OR cognition[tiab] OR cardiometabolic[tiab] OR cardiovascular[tiab] OR mortality[tiab] OR inflammation[tiab] OR biomarkers[tiab] OR safety[tiab]) AND English[lang] AND ("2000"[dp] : "2100"[dp]) NOT ("pediatric only"[tiab] OR "pregnancy only"[tiab] OR "case report only"[tiab] OR "cosmetic device only"[tiab] OR "sports performance only"[tiab])
• ("telomere measurement methods" OR telomere) AND (aging OR "older adults" OR elderly OR geriatric OR longevity OR healthspan OR frailty OR sarcopenia OR "muscle function" OR "physical function" OR cognition OR cardiometabolic OR cardiovascular OR mortality OR inflammation OR biomarkers OR safety) AND LANG:eng AND PUB_YEAR:[2000 TO 2100] NOT ("pediatric only" OR "pregnancy only" OR "case report only" OR "cosmetic device only" OR "sports performance only")
• ("telomere measurement methods"[tiab] OR telomere[tiab]) AND (mechanism[tiab] OR "dose rationale"[tiab] OR "field history"[tiab] OR "preclinical lifespan signal"[tiab] OR "mitochondrial function"[tiab] OR "autophagy mechanism"[tiab] OR "inflammation biology"[tiab] OR "safety history"[tiab]) AND English[lang] AND ("2000"[dp] : "2100"[dp]) NOT ("pediatric only"[tiab] OR "pregnancy only"[tiab] OR "case report only"[tiab] OR "cosmetic device only"[tiab] OR "sports performance only"[tiab])
• ("telomere measurement methods" OR telomere) AND (mechanism OR "dose rationale" OR "field history" OR "preclinical lifespan signal" OR "mitochondrial function" OR "autophagy mechanism" OR "inflammation biology" OR "safety history") AND LANG:eng AND PUB_YEAR:[2000 TO 2100] NOT ("pediatric only" OR "pregnancy only" OR "case report only" OR "cosmetic device only" OR "sports performance only")
• ("telomere measurement methods" OR telomere) AND (mechanism OR "dose rationale" OR "field history" OR "preclinical lifespan signal" OR "mitochondrial function" OR "autophagy mechanism" OR "inflammation biology" OR "safety history") NOT ("pediatric only" OR "pregnancy only" OR "case report only" OR "cosmetic device only" OR "sports performance only")
• telomere measurement methods telomere mechanism dose rationale field history preclinical lifespan signal mitochondrial function autophagy mechanism inflammation biology safety history

Eligibility criteria

• Sources whose primary content addresses telomere measurement methods.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 165 records in the receipt-candidate union, 52 were classified as source candidates and 40 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
source candidate union	165
Classified source candidates	52
No extractable claims	12
None-only claim binding	12
Mixed partial-or-none claim-binding candidates	66
Partial-only claim-binding candidates	22
Strict high-confidence sources	1
Admitted final sources	40

Exclusion reasons

• No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

Directness coding criteria

A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

Risk-of-bias appraisal

Risk-of-bias framework assignment follows study design (risk-of-bias appraisal for RCTs, non-randomized-study appraisal for non-randomised studies, review-quality appraisal for systematic reviews / meta-analyses). Public appraisal claims are limited to populated risk_of_bias.json rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, deficiency prevalence, frailty, immune and inflammation, longevity, mortality and survival, muscle function); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Manuscript drafting used large language models under a deterministic audit-trail protocol. Claim and citation trace artifacts are recorded in the supplementary manifest.json; source-provider outcomes are limited to the frozen inventory reported above.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Results

Evidence domain	Corpus slice	Direction profile	Directness	Main limitation
Telomere Measurement Methods / Contextual Adjacent Evidence	n=25; claims=319	positive=1, negative=2, null=2, mixed=1, unclear=19 (n=25)	17 direct; 5 indirect; 3 review	limited corpus depth in this outcome class
Telomere Measurement Methods / Cardiometabolic	n=4; claims=30	positive=0, negative=0, null=0, mixed=0, unclear=4 (n=4)	3 direct; 1 review	limited corpus depth in this outcome class
Telomere Measurement Methods / Immune and Inflammation	n=4; claims=72	positive=0, negative=0, null=2, mixed=0, unclear=2 (n=4)	2 direct; 1 indirect; 1 review	limited corpus depth in this outcome class
Telomere Measurement Methods / Longevity	n=2; claims=44	positive=1, negative=0, null=0, mixed=0, unclear=1 (n=2)	1 direct; 1 review	limited corpus depth in this outcome class
Telomere Measurement Methods / Animal/Preclinical Context	n=1; claims=11	positive=0, negative=0, null=0, mixed=0, unclear=1 (n=1)	1 mechanistic	single-source slice; hypothesis-generating
Telomere Measurement Methods / Population / prevalence	n=1; claims=14	positive=0, negative=0, null=0, mixed=0, unclear=1 (n=1)	1 indirect	single-source slice; hypothesis-generating
Telomere Measurement Methods / Frailty	n=1; claims=10	positive=0, negative=0, null=0, mixed=0, unclear=1 (n=1)	1 indirect	single-source slice; hypothesis-generating
Telomere Measurement Methods / Mortality and Survival	n=1; claims=13	positive=0, negative=0, null=0, mixed=0, unclear=1 (n=1)	1 indirect	single-source slice; hypothesis-generating
Telomere Measurement Methods / Muscle Function	n=1; claims=7	positive=0, negative=0, null=0, mixed=0, unclear=1 (n=1)	1 review	single-source slice; hypothesis-generating

Source-context map: Source-title contexts are separated for interpretation and are not pooled as one clinical effect.

• Aging and geroscience context: 4 sources; significant source statistic in 1/4 sources; receipt-level direction coded unclear.
• Infectious-disease and immunology context: 2 sources; significant source statistic in 1/2 sources; receipt-level direction coded unclear.
• Oncology and cancer context: 2 sources; significant source statistic in 2/2 sources; receipt-level direction coded unclear.
• Transplant and fibrosis context: 2 sources; significant source statistic in 1/2 sources; receipt-level direction coded unclear.
• Skeletal and muscle context: 1 sources; unclear signal in 1/1 sources.

Longevity Outcomes

Mortality and Survival Outcomes

• Sarkar 2026 [bundle:11] (Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer; representative statistic p = 0.0005; source-level statistic reported; outcome=Biomarker/Adjacent Mortality and Survival; direction=unclear; directness=indirect; tier=B2).

Contextual Adjacent Evidence Outcomes

• Ribeiro 2021 [bundle:1] (Short-Term Aerobic Exercise Did Not Change Telomere Length While It Reduced Testosterone Levels and Obesity Indexes in; representative statistic p ≤ 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1).
• Jaeger 2024 [bundle:4] (A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; representative statistic p = 0.01; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1).
• Salvador 2016 [bundle:34] (A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo; representative statistic p = 0.005; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1).
• Sindi 2020 [bundle:7] (Telomere Length Change in a Multidomain Lifestyle Intervention to Prevent Cognitive Decline: A Randomized Clinical Trial; representative statistic p = .039; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1).

Cardiometabolic Outcomes

• Hastings 2024 [bundle:6] (19 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1).
• Kalstad 2019 [bundle:36] (Leukocyte telomere length and serum polyunsaturated fatty acids, dietary habits, cardiovascular risk factors and; 8 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1).
• Ojeda-Rodriguez 2024 [bundle:30] (2 extracted claim(s); receipt-level direction is the coded finding; outcome=Cardiometabolic; direction=unclear; directness=direct; tier=A1).
• Gerede 2026 [bundle:31] (A Systematic Review of Telomere Length and Telomerase Activity in Preeclampsia: Maternal, Placental, and Cord Blood; 1 extracted claim(s); receipt-level direction is the coded finding; outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear; directness=review; tier=B2).

Immune and Inflammation Outcomes

• Su 2025 [bundle:8] (Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis; representative statistic p < 0.00001; source-level statistic reported; outcome=Biomarker/Adjacent Immune and Inflammation; direction=null; directness=review; tier=B1).
• Wojcicki 2023 [bundle:9] (Shorter leukocyte telomere length protects against NAFLD progression in children; 16 extracted claim(s); receipt-level direction is the coded finding; outcome=Immune and Inflammation; direction=unclear; directness=direct; tier=A1).
• Wattanathorn 2025 [bundle:19] (An Anthocyanin- and Anti-Ageing Amino Acids-Enriched Pigmented Rice Innovation Promotes Healthy Ageing Through the; 9 extracted claim(s); receipt-level direction is the coded finding; outcome=Immune and Inflammation; direction=unclear; directness=direct; tier=A1).
• Nanda 2025 [bundle:2] (Chronic inflammation mediates the relationship between physical activity and telomere length; 30 extracted claim(s); receipt-level direction is the coded finding; outcome=Biomarker/Adjacent Immune and Inflammation; direction=null; directness=indirect; tier=B2).

Population / prevalence Outcomes

See the structured evidence table for Population / prevalence signals.

Frailty Outcomes

• Liu 2025 [bundle:18] (representative non-significant statistic p>0.05; not treated as positive or negative directional support unless source direction is coded; outcome=Biomarker/Adjacent Frailty; direction=unclear; directness=indirect; tier=B2).

Muscle Function Outcomes

• Ryall 2025 [bundle:23] (A Systematic Review and Meta-analysis Highlights a Link Between Aerobic Fitness and Telomere Maintenance; representative statistic p = .03; source-level statistic reported; outcome=Muscle Function; direction=unclear; directness=review; tier=B2).

Discussion

Thesis: Across 40 curated reference papers, the evidence base for Telomere shows a context-dependent profile. Positive signals appear in: longevity, Contextual Adjacent Evidence. Negative signals appear in: Contextual Adjacent Evidence. Null findings dominate: immune inflammation, Contextual Adjacent Evidence. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Telomere broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

Threat 1: Several randomized controlled trials reporting telomere maintenance or lengthening also report concurrent improvements in cardiometabolic, hormonal, or inflammatory biomarkers, suggesting that the disconnect between elongation and function may be an artifact of short follow-up or underpowered functional endpoints rather than a true mechanistic disconnect. These findings appear consistent with a model in which the temporal horizon required for telomere elongation to manifest as functional improvement may exceed the 12- to 24-month windows most trials employ, and the evidence suggests that caloric restriction confers benefits through pathways that do not necessarily pass through measurable telomere length change.

Resolution criteria: Settling the threats identified above requires specific study designs that the current evidence base lacks.

Evidence Summary

The evidence base for this synthesis comprises 40 included sources. By directness, the breakdown is: direct (n=23), indirect (n=10), review (n=7). 24 of 40 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: adults; older adults; frail / sarcopenic adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus is dominated by randomised controlled trials that enrolled middle-aged or older adults from high-income settings, leaving populations such as children, adolescents, and individuals from low- and middle-income countries largely absent [Ribeiro 2021] [bundle:1] [exact source: https://doi.org/10.3390/ijerph182111274]. Only one trial in the corpus explicitly focused on paediatric participants, which limits the ability to generalise findings about telomere measurement to younger age groups [Wojcicki 2023] [bundle:9] [exact source: https://doi.org/10.1038/s41598-023-31149-y]. Most included studies assessed leukocyte telomere length as their primary metric, meaning the synthesis cannot speak to the validity or clinical utility of alternative specimen sources such as buccal or tissue-derived measurements [Oaks 2020] [bundle:14] [exact source: https://doi.org/10.1080/10253890.2020.1728528]. The corpus lacks large-scale head-to-head comparisons of different assay platforms, so the synthesis cannot determine which measurement method yields the most reproducible or clinically meaningful results across study designs [Puhlmann 2019] [bundle:37] [exact source: https://doi.org/10.1001/jamanetworkopen.2019.9687].

Several clinically important outcomes, including hard mortality endpoints, are represented by only a single study, precluding internal replication within the corpus [Sarkar 2026] [bundle:11] [exact source: https://doi.org/10.3390/cancers18030490]. Similarly, the link between telomere length and neurodegenerative disease risk is drawn from one observational cohort, so the finding cannot be cross-validated against other studies in this synthesis [Chen 2026] [bundle:3] [exact source: https://doi.org/10.1007/s00415-025-13479-1]. The association between telomere length and idiopathic pulmonary fibrosis relies on a single meta-analysis, leaving the synthesis without corroborating evidence from independent primary studies within the curated set [Fachrucha 2026] [bundle:17] [exact source: https://doi.org/10.2174/0118743064421488251017061020]. Telomere length dynamics in adults living with human immunodeficiency virus are summarised by one systematic review, but no primary randomised evidence from this population was included, restricting causal inference [Massamba 2026] [bundle:29] [exact source: https://doi.org/10.1186/s12879-026-13243-4].

Most trials enrolled participants free of advanced disease, which limits external validity to clinical populations such as those with established frailty or sarcopenia where telomere biology may differ [Farhat 2025] [bundle:5] [exact source: https://doi.org/10.3390/nu17182974]. The evidence on telomere maintenance and aerobic fitness is drawn from a systematic review rather than interventional trials, meaning the synthesis cannot establish a causal direction for this association [Ryall 2025] [bundle:23] [exact source: https://doi.org/10.1093/gerona/glaf068]. Telomere-based biomarker associations with colorectal cancer recurrence were reported by a single prospective cohort, and the clinical utility of telomere measurement for guiding treatment decisions remains untested [Gil-Korilis 2026] [bundle:25] [exact source: https://doi.org/10.1186/s10020-026-01423-6]. No included study directly tested whether changes in telomere length mediate the effect of a behavioural or pharmacological intervention on a hard clinical endpoint such as cardiovascular events or cancer incidence [Opstad 2022] [bundle:16] [exact source: https://doi.org/10.3390/nu14163346].

The corpus does not include trials that assessed telomere measurement in the context of preterm birth or pregnancy complications, leaving the reported link between longer leukocyte telomere length and premature rupture of membranes unreplicated [Xiao 2026] [bundle:20] [exact source: https://doi.org/10.1038/s41598-026-46566-y]. Periodontitis was studied only through observational and Mendelian-randomisation designs, so whether telomere shortening is a cause, consequence, or epiphenomenon of oral disease cannot be resolved from this evidence base [Hu 2022] [bundle:27] [exact source: https://doi.org/10.3389/fimmu.2022.1057602]. Finally, no study in the corpus evaluated patient-reported outcomes or quality-of-life measures in relation to telomere length change, so the clinical significance of observed biomarker shifts remains uncertain [Sindi 2020] [bundle:7] [exact source: https://doi.org/10.1093/gerona/glaa279].

Conclusion

Pending further large-scale, long-term randomized trials, the current evidence does not support the routine clinical use of telomere length measurement for guiding individual treatment decisions or as a primary endpoint for evaluating broad longevity interventions [bundle:4]. The available data suggest that while telomere length is a plausible mechanistic marker of cellular aging and is associated with disease risk in observational studies, interventions that lengthen telomeres do not yet demonstrate consistent, clinically meaningful benefits on functional outcomes [bundle:8].

The recommended next step is to design and execute randomized trials that use hard clinical endpoints and functional outcomes, rather than telomere length alone, to evaluate whether interventions targeting telomere biology can deliver tangible health benefits.

Corpus boundary

The retained record spans these source roles: direct, indirect, review. It also spans multiple source tiers without treating those tiers as interchangeable. This corpus-specific structure sets the interpretive perimeter and keeps distinct source roles separate.

Outcome coding spans cardiometabolic, contextual other, deficiency prevalence, frailty, immune inflammation, longevity, mortality survival, muscle function, while direction coding spans mixed, negative, null, positive, unclear. The direct subset sets the ceiling for applied interpretation. Indirect, mechanistic, protocol, and review rows add context, but no source role stands in for another.

This boundary keeps the conclusion within the recorded populations, comparators, endpoints, and follow-up windows. It does not extend the paper into treatment guidance, a pooled estimate, or population-wide advice. Future updates must retain the same source-role, endpoint-fit, and population-fit distinctions. That scope remains explicit whenever the corpus is updated or reinterpreted.

Background

Geroscience posits that biological aging is driven by a set of interconnected hallmarks, including genomic instability, telomere attrition, epigenetic alterations, and cellular senescence, which collectively underpin the pathogenesis of most chronic diseases. Among these, telomere biology has attracted particular regulatory and scientific attention because telomere length represents a measurable, albeit imperfect, biomarker of cellular replicative history. Regulatory interest in telomere-targeted therapies is growing, yet substantial uncertainty remains regarding the clinical validity of telomere length as a primary surrogate endpoint, a concern consistent with general methodological cautions about surrogate associations (Ioannidis 2005). The geroscience framework suggests that interventions targeting fundamental aging mechanisms could delay or prevent multiple age-related conditions simultaneously. However, the translation from mechanistic plausibility to clinical benefit requires rigorous validation through randomized controlled trials with functional endpoints, a standard that telomere-focused research has yet to consistently meet. This synthesis evaluates the evidence base for telomere length as a target and biomarker, mapping positive, negative, and null findings across outcome domains.

The clinical trial landscape for telomere-modulating interventions is characterized by numerous small-to-medium sized randomized controlled trials with mechanistic or biomarker endpoints, predominantly of relatively short duration. The heterogeneity in interventions, populations, dosing, and follow-up durations complicates the synthesis of trial-level evidence.

Methodological questions critically shape the interpretation of the telomere measurement evidence base. A primary challenge is the selection and validation of appropriate endpoints; telomere length is frequently used as a surrogate biomarker, yet its correlation with hard clinical outcomes like mortality or functional decline remains inconsistent, reinforcing the caution that surrogate associations do not guarantee clinical validity (Ioannidis 2005). Significant heterogeneity exists across studies in telomere length measurement techniques (for example, quantitative polymerase chain reaction versus Southern blot), the tissue source (for example, leukocytes versus buccal cells), and the analytical metrics reported (for example, mean telomere length versus percentage of short telomeres). Furthermore, the optimal treatment duration for interventions targeting telomere biology is unknown; trials range from weeks to years, with no clear consensus on the minimum duration required to observe meaningful biological effects. Concurrent lifestyle interventions, such as physical activity and diet, are often poorly controlled or variably implemented, adding confounding layers. Future research must prioritize standardized measurement protocols, longer follow-up periods with clinically relevant endpoints, and trials designed to disentangle the direct effects of interventions from concurrent behavioral changes.

Cross-Domain Synthesis

A fundamental tension exists between telomere length as a biomarker of biological age and its inconsistent performance as a predictor of functional outcomes across different organ systems [Wilbourn 2018] [bundle:33] [exact source: https://doi.org/10.1098/rstb.2016.0447]. While a meta-analysis of non-model vertebrates found a significant negative association between telomere length and mortality risk, substantial heterogeneity among study effect sizes suggests this relationship is context-dependent and not universally applicable [Wilbourn 2018] [bundle:33] [exact source: https://doi.org/10.1098/rstb.2016.0447]. This contrasts with the clear, direct evidence from a randomized controlled trial showing selenium and coenzyme Q10 supplementation prevented telomere attrition and was associated with reduced cardiovascular mortality, indicating a specific, mechanistically plausible link in a clinical population [Opstad 2022] [bundle:16] [exact source: https://doi.org/10.3390/nu14163346]. The boundary condition may relate to the presence of established disease or specific nutrient deficiencies, where telomere preservation could directly impact cellular senescence in a target organ, unlike in healthy, heterogeneous populations where other factors dominate [Opstad 2022] [bundle:16] [exact source: https://doi.org/10.3390/nu14163346]. A significant tension emerges when comparing direct clinical RCT evidence with mechanistic or biomarker-based RCT evidence regarding telomere length interventions [Wojcicki 2023] [bundle:9] [exact source: https://doi.org/10.1038/s41598-023-31149-y]. The direct RCT evidence from the TONIC trial shows that in children with NAFLD, shorter leukocyte telomere length was protective against disease progression, establishing a clear clinical association with a specific disease outcome [Wojcicki 2023] [bundle:9] [exact source: https://doi.org/10.1038/s41598-023-31149-y]. The mechanisms likely diverge because disease progression (NAFLD) involves complex tissue-specific pathology where telomere length may be a downstream marker, while frailty and systemic inflammation represent broader aging phenotypes where telomere elongation alone is insufficient [Su 2025] [bundle:8] [exact source: https://doi.org/10.1007/s10565-025-10115-6].

This suggests the boundary condition is disease specificity: telomere interventions may show clinical signal in conditions where cellular senescence is a primary driver, but not in generalized aging syndromes with multifactorial etiology [Wojcicki 2023] [bundle:9] [exact source: https://doi.org/10.1038/s41598-023-31149-y]. The evidence presents a paradoxical situation where longer leukocyte telomere length is associated with both protective and detrimental health outcomes in different clinical contexts [Chen 2026] [bundle:3] [exact source: https://doi.org/10.1007/s00415-025-13479-1]. In a large prospective cohort, shorter leukocyte telomere length was associated with an increased risk of Alzheimer's disease and related dementias, while longer telomere length was associated with a substantially increased risk of multiple sclerosis [Chen 2026] [bundle:3] [exact source: https://doi.org/10.1007/s00415-025-13479-1]. This directional conflict is further highlighted by another observational study finding that longer leukocyte telomere length significantly increased the odds of premature rupture of membranes in pregnancy, a condition unrelated to classical aging [Xiao 2026] [bundle:20] [exact source: https://doi.org/10.1038/s41598-026-46566-y]. The mechanism-level explanation may involve tissue-specific roles of telomerase activity or the fact that leukocyte length is a systemic average that does not reflect telomere dynamics in specific affected cell populations like neural progenitors or immune cells [Chen 2026] [bundle:3] [exact source: https://doi.org/10.1007/s00415-025-13479-1]. A potential boundary condition is the underlying disease biology: in neurodegenerative diseases, cellular senescence may contribute to pathology, making shorter telomeres a risk factor, whereas in autoimmune conditions like MS, enhanced replicative capacity of immune cells could be pathogenic [Chen 2026] [bundle:3] [exact source: https://doi.org/10.1007/s00415-025-13479-1]. Resolving this requires disease-specific mechanistic studies to determine whether interventions should aim to lengthen or shorten telomeres in different immune or neural cell subsets, moving beyond a simplistic "longer is better" paradigm [Chen 2026] [bundle:3] [exact source: https://doi.org/10.1007/s00415-025-13479-1].

A core tension exists between the promise of telomere length as a universal marker of aging and the mixed, often null results from interventions targeting it in human RCTs [Hastings 2024] [bundle:6] [exact source: https://doi.org/10.1111/acel.14149]. For instance, the CALERIE 2 trial, a large clinical/functional endpoint RCT of caloric restriction, found no significant differences in leukocyte telomere length change over 24 months between intervention and control groups, despite prior evidence for significant cardiometabolic improvements [Hastings 2024] [bundle:6] [exact source: https://doi.org/10.1111/acel.14149]. These null findings on the biomarker level contrast with the positive functional outcomes (cardiometabolic health, cognition) observed, suggesting that telomere length may not be the primary mechanism through which these interventions exert their benefits [Hastings 2024] [bundle:6] [exact source: https://doi.org/10.1111/acel.14149]. There is a significant indirectness gap between observational evidence linking telomere length to health outcomes and the direct RCT evidence testing interventions to modify telomere length [Nanda 2025] [bundle:2] [exact source: https://doi.org/10.1007/s11357-025-01818-z]. Observational cohort studies, such as one in a large population, suggest that chronic inflammation (measured by C-reactive protein) partially mediates the relationship between physical activity and leukocyte telomere length, implying a modifiable pathway [Nanda 2025] [bundle:2] [exact source: https://doi.org/10.1007/s11357-025-01818-z]. However, direct RCTs of anti-inflammatory or lifestyle interventions often fail to show significant effects on telomere length, creating a disconnect between observed associations and interventional results [Nanda 2025] [bundle:2] [exact source: https://doi.org/10.1007/s11357-025-01818-z]. The mechanism may be that observational associations capture lifelong exposures, while RCTs test short-term interventions that cannot overcome decades of accumulated telomere attrition or influence the slow kinetics of telomere dynamics [Nanda 2025] [bundle:2] [exact source: https://doi.org/10.1007/s11357-025-01818-z].

A boundary condition could be the intervention duration and population age: starting interventions earlier in life or extending trial duration may be necessary to observe meaningful telomere length changes [Nanda 2025] [bundle:2] [exact source: https://doi.org/10.1007/s11357-025-01818-z]. Evidence to resolve this would come from long-term, lifelong RCTs or trials initiated in young adulthood, which are ethically and logistically challenging but necessary to test the causal nature of these associations [Nanda 2025] [bundle:2] [exact source: https://doi.org/10.1007/s11357-025-01818-z]. The corpus reveals a tension between telomere length's association with frailty and muscle-related outcomes in observational reviews and the absence of supportive evidence from direct RCTs for those specific outcomes [Ryall 2025] [bundle:23] [exact source: https://doi.org/10.1093/gerona/glaf068]. A systematic review and meta-analysis highlights a link between aerobic fitness and telomere maintenance, suggesting a plausible mechanistic connection between physical capacity and cellular aging [Ryall 2025] [bundle:23] [exact source: https://doi.org/10.1093/gerona/glaf068]. The mechanism may be that fitness reflects a lifetime of mitochondrial health, oxidative stress resistance, and proteostasis that correlates with telomere length, whereas a pharmacological intervention targeting telomerase addresses only one piece of this complex system [Ryall 2025] [bundle:23] [exact source: https://doi.org/10.1093/gerona/glaf068]. The boundary condition is likely the distinction between correlative biomarkers and causal drivers: aerobic fitness may be a marker of systemic health that also preserves telomeres, not a consequence of telomere length itself [Ryall 2025] [bundle:23] [exact source: https://doi.org/10.1093/gerona/glaf068]. To resolve this, RCTs combining exercise training with telomere measurements and functional assessments are needed to disentangle whether telomere preservation is a mediator of exercise benefits or merely a correlated biomarker [Ryall 2025] [bundle:23] [exact source: https://doi.org/10.1093/gerona/glaf068].

Evidence Landscape

Findings Map

Findings Map completeness note: all 40 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. source-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting.

Evidence domain	Source	Direction	Directness	Tier	Evidence role	Finding
Animal/Preclinical Context (Contextual Adjacent Evidence)	Kim 2025: Effects of Hawthorn Fruit Supplementation on Facial Skin Phenotypes and Leukocyte Telomere Length Stratified by TERT Polymorphisms	direction=unclear	directness=animal/preclinical context	A1	outcome=Biomarker/Adjacent Animal/Preclinical Context (Contextual Adjacent Evidence); direction=unclear	finding=representative statistic P < 0.05; source-level statistic reported
Cardiometabolic	Gerede 2026: A Systematic Review of Telomere Length and Telomerase Activity in Preeclampsia: Maternal, Placental, and Cord Blood Perspectives	direction=unclear	directness=review	B2	outcome=Biomarker/Adjacent Cardiometabolic; direction=unclear	finding=1 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Hastings 2024: Effect of long‐term caloric restriction on telomere length in healthy adults: CALERIE™ 2 trial analysis	direction=unclear	directness=direct	A1	outcome=Cardiometabolic; direction=unclear	finding=19 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Kalstad 2019: Leukocyte telomere length and serum polyunsaturated fatty acids, dietary habits, cardiovascular risk factors and features of myocardial infarction in elderly patients	direction=unclear	directness=direct	A1	outcome=Cardiometabolic; direction=unclear	finding=8 extracted claim(s); source-level direction is the coded finding
Cardiometabolic	Ojeda-Rodriguez 2024: Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: CORDIOPREV randomised controlled trial	direction=unclear	directness=direct	A1	outcome=Cardiometabolic; direction=unclear	finding=2 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Agirbasli 2022: Leukocyte telomere length as a compensatory mechanism in vitamin D metabolism	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P < 0.001; source-level statistic reported
Contextual Adjacent Evidence	Borghini 2026: Combined physical and cognitive training enhances telomere length in mild cognitive impairment patients	direction=negative	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=negative	finding=representative statistic P = 0.02; source-level statistic reported
Contextual Adjacent Evidence	Breitling 2016: Frailty is associated with the epigenetic clock but not with telomere length in a German cohort	direction=unclear	directness=indirect	B2	outcome=Biomarker/Adjacent Evidence; direction=unclear	finding=representative non-significant statistic P = 0.63; not treated as positive or negative directional support unless source direction is coded
Contextual Adjacent Evidence	Canudas 2019: Pistachio consumption modulates DNA oxidation and genes related to telomere maintenance: a crossover randomized clinical trial	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P = 0.009; source-level statistic reported
Contextual Adjacent Evidence	Chen 2026: Association between leukocyte telomere length and neurodegenerative diseases: a prospective cohort in the UK Biobank	direction=mixed	directness=indirect	B2	outcome=Biomarker/Adjacent Evidence; direction=mixed	finding=representative statistic P < 0.001; source-level statistic reported
Contextual Adjacent Evidence	Fachrucha 2026: Shortened Telomere Length as a Risk Factor for Idiopathic Pulmonary Fibrosis: A Meta-Analysis	direction=unclear	directness=review	B2	outcome=Biomarker/Adjacent Evidence; direction=unclear	finding=representative statistic P < 0.00001; source-level statistic reported
Contextual Adjacent Evidence	Farhat 2025: Effects of Pomegranate Extract on IGF-1 Levels and Telomere Length in Older Adults (55–70 Years): Findings from a Randomised Double-Blinded Controlled Trial	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=20 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Franzoni 2022: Aerobic exercise and telomere length in patients with systolic heart failure: protocol study for a randomized controlled trial	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=3 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Freitas-Simoes 2018: Walnut Consumption for Two Years and Leukocyte Telomere Attrition in Mediterranean Elders: Results of a Randomized Controlled Trial	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=39 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Gil-Korilis 2026: Unraveling the telomere-mitochondrial axis in colorectal cancer: Results from a prospectively followed cohort	direction=positive	directness=indirect	B2	outcome=Contextual Adjacent Evidence; direction=positive	finding=representative statistic P = 0.041; source-level statistic reported
Contextual Adjacent Evidence	Hu 2022: Reverse causal relationship between periodontitis and shortened telomere length: Bidirectional two-sample Mendelian random analysis	direction=negative	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=negative	finding=representative non-significant statistic P = 0.7242; not treated as positive or negative directional support unless source direction is coded
Contextual Adjacent Evidence	Jaeger 2024: A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized, Double-Blind, Placebo-Controlled Study	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P = 0.01; source-level statistic reported
Contextual Adjacent Evidence	Mackintosh 2021: TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=8 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Massamba 2026: Telomere length dynamics in adults living with HIV: A systematic review	direction=unclear	directness=review	B2	outcome=Biomarker/Adjacent Evidence; direction=unclear	finding=2 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Oaks 2020: Impact of a nutritional supplement during gestation and early childhood on child salivary cortisol, hair cortisol, and telomere length at 4–6 years of age: a follow-up of a randomized controlled trial	direction=null	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=null	finding=12 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Pitkanen 2021: Effects of Randomized Controlled Infancy-Onset Dietary Intervention on Leukocyte Telomere Length—The Special Turku Coronary Risk Factor Intervention Project (STRIP)	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P = 0.009; source-level statistic reported
Contextual Adjacent Evidence	Puhlmann 2019: Association of Short-term Change in Leukocyte Telomere Length With Cortical Thickness and Outcomes of Mental Training Among Healthy Adults	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=6 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Ribeiro 2021: Short-Term Aerobic Exercise Did Not Change Telomere Length While It Reduced Testosterone Levels and Obesity Indexes in PCOS: A Randomized Controlled Clinical Trial Study	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P ≤ 0.001; source-level statistic reported
Contextual Adjacent Evidence	Salvador 2016: A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P = 0.005; source-level statistic reported
Contextual Adjacent Evidence	Sindi 2017: Baseline Telomere Length and Effects of a Multidomain Lifestyle Intervention on Cognition: The FINGER Randomized Controlled Trial	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=2 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Sindi 2020: Telomere Length Change in a Multidomain Lifestyle Intervention to Prevent Cognitive Decline: A Randomized Clinical Trial	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=representative statistic P = 0.039; source-level statistic reported
Contextual Adjacent Evidence	Sun 2026: The association of periodontitis with telomere length: a meta-analysis	direction=null	directness=review	B2	outcome=Biomarker/Adjacent Evidence; direction=null	finding=5 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Tian 2025: Association of life’s essential 8 with leukocyte telomere length and mitochondrial DNA copy number: Findings from the population-based UK Biobank study	direction=unclear	directness=indirect	B2	outcome=Biomarker/Adjacent Evidence; direction=unclear	finding=representative statistic P < 0.05; source-level statistic reported
Contextual Adjacent Evidence	Werner 2018: Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study	direction=unclear	directness=direct	A1	outcome=Contextual Adjacent Evidence; direction=unclear	finding=4 extracted claim(s); source-level direction is the coded finding
Contextual Adjacent Evidence	Xiao 2026: Longer leukocyte telomere length increases the odds of premature rupture of membranes: a cross-sectional study based on UK Biobank	direction=unclear	directness=indirect	B2	outcome=Biomarker/Adjacent Evidence; direction=unclear	finding=8 extracted claim(s); source-level direction is the coded finding
Population / prevalence	Shellard 2026: Unsuppressed Viremia and Lower CD4 Count Associated With Faster Telomere Attrition in African Children With Perinatal Human Immunodeficiency Virus on Long-term Antiretroviral Therapy	direction=unclear	directness=indirect	B2	outcome=Population / prevalence; direction=unclear	finding=representative statistic P = 0.009; source-level statistic reported
Frailty	Liu 2025: Association between human herpesvirus 6 status and sarcopenia risk: a UK biobank cohort study with sex-specific patterns and telomere length modification	direction=unclear	directness=indirect	B2	outcome=Biomarker/Adjacent Frailty; direction=unclear	finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded
Immune and Inflammation	Nanda 2025: Chronic inflammation mediates the relationship between physical activity and telomere length	direction=null	directness=indirect	B2	outcome=Biomarker/Adjacent Immune and Inflammation; direction=null	finding=30 extracted claim(s); source-level direction is the coded finding
Immune and Inflammation	Su 2025: Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis	direction=null	directness=review	B1	outcome=Biomarker/Adjacent Immune and Inflammation; direction=null	finding=representative statistic P < 0.00001; source-level statistic reported
Immune and Inflammation	Wattanathorn 2025: An Anthocyanin- and Anti-Ageing Amino Acids-Enriched Pigmented Rice Innovation Promotes Healthy Ageing Through the Modulation of Telomere, Oxidative Stress and Inflammation Reduction: A Randomized Clinical Trial	direction=unclear	directness=direct	A1	outcome=Immune and Inflammation; direction=unclear	finding=9 extracted claim(s); source-level direction is the coded finding
Immune and Inflammation	Wojcicki 2023: Shorter leukocyte telomere length protects against NAFLD progression in children	direction=unclear	directness=direct	A1	outcome=Immune and Inflammation; direction=unclear	finding=16 extracted claim(s); source-level direction is the coded finding
Longevity	Opstad 2022: Selenium and Coenzyme Q 10 Intervention Prevents Telomere Attrition, with Association to Reduced Cardiovascular Mortality—Sub-Study of a Randomized Clinical Trial	direction=positive	directness=direct	A1	outcome=Longevity; direction=positive	finding=representative non-significant statistic P = 0.23; not treated as positive or negative directional support unless source direction is coded
Longevity	Wilbourn 2018: The relationship between telomere length and mortality risk in non-model vertebrate systems: a meta-analysis	direction=unclear	directness=review	B2	outcome=Biomarker/Adjacent Longevity; direction=unclear	finding=representative statistic P < 0.001; source-level statistic reported
Mortality and Survival	Sarkar 2026: Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer	direction=unclear	directness=indirect	B2	outcome=Biomarker/Adjacent Mortality and Survival; direction=unclear	finding=representative statistic P = 0.0005; source-level statistic reported
Muscle Function	Ryall 2025: A Systematic Review and Meta-analysis Highlights a Link Between Aerobic Fitness and Telomere Maintenance	direction=unclear	directness=review	B2	outcome=Muscle Function; direction=unclear	finding=representative statistic P = 0.03; source-level statistic reported

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Ribeiro 2021 [bundle:1]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.
• Freitas-Simoes 2018 [bundle:32]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.
• Jaeger 2024 [bundle:4]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.
• Farhat 2025 [bundle:5]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.
• Salvador 2016 [bundle:34]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.
• Hastings 2024 [bundle:6]; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
• Sindi 2020 [bundle:7]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.
• Wojcicki 2023 [bundle:9]; tier=A1; directness=direct; endpoint=immune inflammation; direction=unclear.
• Agirbasli 2022 [bundle:12]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.
• Canudas 2019 [bundle:35]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Ribeiro 2021 [bundle:1]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=52.
• Freitas-Simoes 2018 [bundle:32]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=39.
• Jaeger 2024 [bundle:4]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=23.
• Farhat 2025 [bundle:5]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=20.
• Salvador 2016 [bundle:34]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=20.
• Hastings 2024 [bundle:6]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=19.
• Sindi 2020 [bundle:7]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=19.
• Wojcicki 2023 [bundle:9]: outcome=immune inflammation; directness=direct; tier=A1; direction=unclear; claims=16.
• Agirbasli 2022 [bundle:12]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=13.
• Canudas 2019 [bundle:35]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=13.
• Borghini 2026 [bundle:13]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=negative; claims=12.
• Oaks 2020 [bundle:14]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=12.
• Opstad 2022 [bundle:16]: outcome=longevity; directness=direct; tier=A1; direction=positive; claims=11.
• Wattanathorn 2025 [bundle:19]: outcome=immune inflammation; directness=direct; tier=A1; direction=unclear; claims=9.
• Kalstad 2019 [bundle:36]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=8.
• Mackintosh 2021 [bundle:22]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=8.
• Pitkanen 2021 [bundle:21]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=8.
• Puhlmann 2019 [bundle:37]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=6.
• Hu 2022 [bundle:27]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=negative; claims=4.
• Werner 2018 [bundle:38]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=4.
• Franzoni 2022 [bundle:28]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=3.
• Ojeda-Rodriguez 2024 [bundle:30]: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=2.
• Sindi 2017 [bundle:39]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=2.
• Kim 2025 [bundle:15]: outcome=contextual adjacent evidence; directness=indirect; tier=A1; direction=unclear; claims=11.
• Su 2025 [bundle:8]: outcome=immune inflammation; directness=review; tier=B1; direction=null; claims=17.
• Wilbourn 2018 [bundle:33]: outcome=longevity; directness=review; tier=B2; direction=unclear; claims=33.
• Nanda 2025 [bundle:2]: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=30.
• Chen 2026 [bundle:3]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=mixed; claims=27.
• Shellard 2026 [bundle:10]: outcome=deficiency prevalence; directness=indirect; tier=B2; direction=unclear; claims=14.
• Sarkar 2026 [bundle:11]: outcome=mortality survival; directness=indirect; tier=B2; direction=unclear; claims=13.
• Fachrucha 2026 [bundle:17]: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=10.
• Liu 2025 [bundle:18]: outcome=frailty; directness=indirect; tier=B2; direction=unclear; claims=10.
• Xiao 2026 [bundle:20]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=8.
• Ryall 2025 [bundle:23]: outcome=muscle function; directness=review; tier=B2; direction=unclear; claims=7.
• Sun 2026 [bundle:24]: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=5.
• Gil-Korilis 2026 [bundle:25]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=4.
• Tian 2025 [bundle:26]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=4.
• Massamba 2026 [bundle:29]: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=2.
• Breitling 2016 [bundle:40]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=1.
• Gerede 2026 [bundle:31]: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=1. Kim 2025 [bundle:15] provides animal/preclinical context only.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 3 indirectness gap: Wojcicki 2023 [bundle:9] vs Su 2025 [bundle:8]; Wojcicki 2023 [bundle:9] (direct, A1) vs Su 2025 [bundle:8] (review) on immune inflammation — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Wojcicki 2023 [bundle:9] vs Nanda 2025 [bundle:2]; Wojcicki 2023 [bundle:9] (direct, A1) vs Nanda 2025 [bundle:2] (indirect) on immune inflammation — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Ojeda-Rodriguez 2024 [bundle:30] vs Gerede 2026 [bundle:31]; Ojeda-Rodriguez 2024 [bundle:30] (direct, A1) vs Gerede 2026 [bundle:31] (review) on cardiometabolic — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Hastings 2024 [bundle:6] vs Gerede 2026 [bundle:31]; Hastings 2024 [bundle:6] (direct, A1) vs Gerede 2026 [bundle:31] (review) on cardiometabolic — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Jaeger 2024 [bundle:4] vs Tian 2025 [bundle:26]; Jaeger 2024 [bundle:4] (direct, A1) vs Tian 2025 [bundle:26] (indirect) on Contextual Adjacent Evidence — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Jaeger 2024 [bundle:4] vs Kim 2025 [bundle:15]; Jaeger 2024 [bundle:4] (direct, A1) vs Kim 2025 [bundle:15] (indirect) on Contextual Adjacent Evidence — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Jaeger 2024 [bundle:4] vs Chen 2026 [bundle:3]; Jaeger 2024 [bundle:4] (direct, A1) vs Chen 2026 [bundle:3] (indirect) on Contextual Adjacent Evidence — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Jaeger 2024 [bundle:4] vs Fachrucha 2026 [bundle:17]; Jaeger 2024 [bundle:4] (direct, A1) vs Fachrucha 2026 [bundle:17] (review) on Contextual Adjacent Evidence — direct vs indirect must be kept separate Kim 2025 [bundle:15] provides animal/preclinical context only.

Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Quantitative Evidence Index — telomere measurement methods

Quantitative Evidence Index: top 17 high-confidence numeric claims from the corpus. Every row traces to a corpus-bound claim and a registered citation.

Numeric verification note: P-values are rendered from extracted source statistics; rounded zero values are reported at their implied decimal floor rather than as impossible zero probabilities.

Study	Endpoint	Arm	Value	Type	Statistic
Liu 2025	sarcopenia	—	OR = 3.77	odds ratio	—
Su 2025	frailty	telomere	P = 0.15	p-value	—
Su 2025	inflammation	telomere	P = 0.07	p-value	—
Ribeiro 2021	inflammation	control	P > 0.05	p-value	—
Wojcicki 2023	inflammation	—	—	95%CI	(0.01–0.13)
Jaeger 2024	body mass index	—	P = 0.1	p-value	—
Ryall 2025	VO2max	—	P = 0.002	p-value	—
Farhat 2025	body mass index	—	P = 0.31	p-value	—
Wilbourn 2018	mortality	—	P < 0.001	p-value	—
Wilbourn 2018	lifespan	—	P = 0.75	p-value	—
Sindi 2020	blood pressure	—	P = 0.039	p-value	—
Pitkanen 2021	blood pressure	—	P = 0.009	p-value	—
Hastings 2024	body mass index	control	25%	%	—
Hastings 2024	adherence	control	20%	%	—
Nanda 2025	inflammation	—	95%	%	—
Kalstad 2019	body mass index	—	50%	%	—
Ribeiro 2021	adherence	—	90%	%	—

References

• Ribeiro 2021. Short-Term Aerobic Exercise Did Not Change Telomere Length While It Reduced Testosterone Levels and Obesity Indexes in PCOS: A Randomized Controlled Clinical Trial Study. International Journal of Environmental Research and Public Health, 2021. DOI: 10.3390/ijerph182111274 PMID: 34769797.
• Freitas-Simoes 2018. Walnut Consumption for Two Years and Leukocyte Telomere Attrition in Mediterranean Elders: Results of a Randomized Controlled Trial. Nutrients, 2018. DOI: 10.3390/nu10121907 PMID: 30518050.
• Wilbourn 2018. The relationship between telomere length and mortality risk in non-model vertebrate systems: a meta-analysis. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018. DOI: 10.1098/rstb.2016.0447 PMID: 29335371.
• Nanda 2025. Chronic inflammation mediates the relationship between physical activity and telomere length. GeroScience, 2025. DOI: 10.1007/s11357-025-01818-z PMID: 40762785.
• Chen 2026. Association between leukocyte telomere length and neurodegenerative diseases: a prospective cohort in the UK Biobank. Journal of Neurology, 2026. DOI: 10.1007/s00415-025-13479-1 PMID: 41670794.
• Jaeger 2024. A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized, Double-Blind, Placebo-Controlled Study. Nutrients, 2024. DOI: 10.3390/nu16172963 PMID: 39275278.
• Farhat 2025. Effects of Pomegranate Extract on IGF-1 Levels and Telomere Length in Older Adults (55–70 Years): Findings from a Randomised Double-Blinded Controlled Trial. Nutrients, 2025. DOI: 10.3390/nu17182974 PMID: 41010500.
• Salvador 2016. A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study. Rejuvenation Research, 2016. DOI: 10.1089/rej.2015.1793 PMID: 26950204.
• Hastings 2024. Effect of long‐term caloric restriction on telomere length in healthy adults: CALERIE™ 2 trial analysis. Aging Cell, 2024. DOI: 10.1111/acel.14149 PMID: 38504468.
• Sindi 2020. Telomere Length Change in a Multidomain Lifestyle Intervention to Prevent Cognitive Decline: A Randomized Clinical Trial. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2020. DOI: 10.1093/gerona/glaa279 PMID: 33175128.
• Su 2025. Effects of TA-65 on telomere length, functional outcomes, and inflammation: a systematic review and meta-analysis. Cell Biology and Toxicology, 2025. DOI: 10.1007/s10565-025-10115-6 PMID: 41286474.
• Wojcicki 2023. Shorter leukocyte telomere length protects against NAFLD progression in children. Scientific Reports, 2023. DOI: 10.1038/s41598-023-31149-y PMID: 37012261.
• Shellard 2026. Unsuppressed Viremia and Lower CD4 Count Associated With Faster Telomere Attrition in African Children With Perinatal Human Immunodeficiency Virus on Long-term Antiretroviral Therapy. The Journal of Infectious Diseases, 2026. DOI: 10.1093/infdis/jiag060 PMID: 41655979.
• Sarkar 2026. Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer. Cancers, 2026. DOI: 10.3390/cancers18030490 PMID: 41681962.
• Canudas 2019. Pistachio consumption modulates DNA oxidation and genes related to telomere maintenance: a crossover randomized clinical trial. The American Journal of Clinical Nutrition, 2019. DOI: 10.1093/ajcn/nqz048 PMID: 31051499.
• Agirbasli 2022. Leukocyte telomere length as a compensatory mechanism in vitamin D metabolism. PLoS ONE, 2022. DOI: 10.1371/journal.pone.0264337 PMID: 35202418.
• Borghini 2026. Combined physical and cognitive training enhances telomere length in mild cognitive impairment patients. BMC Geriatrics, 2026. DOI: 10.1186/s12877-026-07380-3 PMID: 41913117.
• Oaks 2020. Impact of a nutritional supplement during gestation and early childhood on child salivary cortisol, hair cortisol, and telomere length at 4–6 years of age: a follow-up of a randomized controlled trial. Stress (Amsterdam, Netherlands), 2020. DOI: 10.1080/10253890.2020.1728528 PMID: 32063089.
• Kim 2025. Effects of Hawthorn Fruit Supplementation on Facial Skin Phenotypes and Leukocyte Telomere Length Stratified by TERT Polymorphisms. Nutrients, 2025. DOI: 10.3390/nu17121983 PMID: 40573097.
• Opstad 2022. Selenium and Coenzyme Q 10 Intervention Prevents Telomere Attrition, with Association to Reduced Cardiovascular Mortality—Sub-Study of a Randomized Clinical Trial. Nutrients, 2022. DOI: 10.3390/nu14163346 PMID: 36014852.
• Liu 2025. Association between human herpesvirus 6 status and sarcopenia risk: a UK biobank cohort study with sex-specific patterns and telomere length modification. Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1623291 PMID: 41041314.
• Fachrucha 2026. Shortened Telomere Length as a Risk Factor for Idiopathic Pulmonary Fibrosis: A Meta-Analysis. The Open Respiratory Medicine Journal, 2026. DOI: 10.2174/0118743064421488251017061020 PMID: 41728098.
• Wattanathorn 2025. An Anthocyanin-and Anti-Ageing Amino Acids-Enriched Pigmented Rice Innovation Promotes Healthy Ageing Through the Modulation of Telomere, Oxidative Stress and Inflammation Reduction: A Randomized Clinical Trial. International Journal of Molecular Sciences, 2025. DOI: 10.3390/ijms262210911 PMID: 41303396.
• Xiao 2026. Longer leukocyte telomere length increases the odds of premature rupture of membranes: a cross-sectional study based on UK Biobank. Scientific Reports, 2026. DOI: 10.1038/s41598-026-46566-y PMID: 41922689.
• Kalstad 2019. Leukocyte telomere length and serum polyunsaturated fatty acids, dietary habits, cardiovascular risk factors and features of myocardial infarction in elderly patients. BMC Geriatrics, 2019. DOI: 10.1186/s12877-019-1383-9 PMID: 31881852.
• Pitkanen 2021. Effects of Randomized Controlled Infancy-Onset Dietary Intervention on Leukocyte Telomere Length—The Special Turku Coronary Risk Factor Intervention Project (STRIP). Nutrients, 2021. DOI: 10.3390/nu13020318 PMID: 33499376.
• Mackintosh 2021. TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. BMJ Open Respiratory Research, 2021. DOI: 10.1136/bmjresp-2021-001127 PMID: 34857525.
• Ryall 2025. A Systematic Review and Meta-analysis Highlights a Link Between Aerobic Fitness and Telomere Maintenance. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2025. DOI: 10.1093/gerona/glaf068 PMID: 40247641.
• Puhlmann 2019. Association of Short-term Change in Leukocyte Telomere Length With Cortical Thickness and Outcomes of Mental Training Among Healthy Adults. JAMA Network Open, 2019. DOI: 10.1001/jamanetworkopen.2019.9687 PMID: 31553468.
• Sun 2026. The association of periodontitis with telomere length: a meta-analysis. BMC Medical Genomics, 2026. DOI: 10.1186/s12920-026-02323-8 PMID: 41923055.
• Tian 2025. Association of life’s essential 8 with leukocyte telomere length and mitochondrial DNA copy number: Findings from the population-based UK Biobank study. The Journal of Nutrition, Health & Aging, 2025. DOI: 10.1016/j.jnha.2025.100557 PMID: 40250166.
• Gil-Korilis 2026. Unraveling the telomere-mitochondrial axis in colorectal cancer: Results from a prospectively followed cohort. Molecular Medicine, 2026. DOI: 10.1186/s10020-026-01423-6 PMID: 41721457.
• Werner 2018. Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study. European Heart Journal, 2018. DOI: 10.1093/eurheartj/ehy585 PMID: 30496493.
• Hu 2022. Reverse causal relationship between periodontitis and shortened telomere length: Bidirectional two-sample Mendelian random analysis. Frontiers in Immunology, 2022. DOI: 10.3389/fimmu.2022.1057602 PMID: 36601105.
• Franzoni 2022. Aerobic exercise and telomere length in patients with systolic heart failure: protocol study for a randomized controlled trial. Trials, 2022. DOI: 10.1186/s13063-022-06257-1 PMID: 35410445.
• Ojeda-Rodriguez 2024. Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: CORDIOPREV randomised controlled trial. Cardiovascular Diabetology, 2024. DOI: 10.1186/s12933-024-02175-5 PMID: 38493287.
• Massamba 2026. Telomere length dynamics in adults living with HIV: A systematic review. BMC Infectious Diseases, 2026. DOI: 10.1186/s12879-026-13243-4 PMID: 42000997.
• Sindi 2017. Baseline Telomere Length and Effects of a Multidomain Lifestyle Intervention on Cognition: The FINGER Randomized Controlled Trial. Journal of Alzheimer's Disease, 2017. DOI: 10.3233/JAD-170123 PMID: 28777749.
• Gerede 2026. A Systematic Review of Telomere Length and Telomerase Activity in Preeclampsia: Maternal, Placental, and Cord Blood Perspectives. Medical Sciences, 2026. DOI: 10.3390/medsci14010100 PMID: 41892815.
• Breitling 2016. Frailty is associated with the epigenetic clock but not with telomere length in a German cohort. Clinical Epigenetics, 2016. DOI: 10.1186/s13148-016-0186-5 PMID: 26925173.

Research Question

Within the retained source corpus for telomere measurement methods, among adults, do findings for contextual adjacent evidence and cardiometabolic support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

What This Synthesis Adds

This synthesis maps 40 included sources on Telomere Measurement Methods across 8 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

The strongest unresolved contrast is the mechanism vs clinical between Wojcicki 2023 [bundle:9] and Ryall 2025 [bundle:23] on immune and inflammation (severity 3/5), which defines the boundary condition future studies must test rather than smooth over [exact source: https://doi.org/10.1038/s41598-023-31149-y] [exact source: https://doi.org/10.1093/gerona/glaf068].

Prior reviews in the corpus (Su 2025 [bundle:8]) emphasize convergent signals on Telomere Measurement Methods [exact source: https://doi.org/10.1007/s10565-025-10115-6]. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
frailty	0	1	unclear	direct interventional hard-endpoint gap
muscle function	0	1	unclear	direct interventional hard-endpoint gap
longevity	1	1	positive, unclear	replication gap
cardiometabolic	3	1	unclear	replication gap
deficiency prevalence	0	1	unclear	direct interventional hard-endpoint gap
immune and inflammation	2	2	null, unclear	replication gap
mortality and survival	0	1	unclear	direct interventional hard-endpoint gap
contextual adjacent evidence	17	9	mixed, negative, null, positive, unclear	replication gap

Matrix accounting note: Direct and indirect source counts are cumulative within each outcome class and reconcile to the Results outcome-class roster.

Evidence-Gap Priority

Priority	Gap	Rationale
P1	frailty: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear
P2	muscle function: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear
P3	longevity: replication gap	1 direct and 1 indirect sources; direction profile: positive, unclear
P4	cardiometabolic: replication gap	3 direct and 1 indirect sources; direction profile: unclear
P5	deficiency prevalence: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: unclear

Next-Study Design Recommendation

The next high-yield study for Telomere Measurement Methods should target the frailty evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.